Milestone Pharmaceuticals Inc. is developing a short-acting calcium channel blocker to treat a heart arrhythmia called paroxysmal supraventricular tachycardia. PSVT usually isn’t life-threatening and typically resolves on its own, but it is alarming and often leads patients to the emergency room. Milestone envisions that its drug will be used at home as episodes arise. It has a half-life of just one to four minutes and is delivered intranasally to get to the heart quickly.
Milestone Pharmaceuticals Inc.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
